Guardion Health Sciences, Inc.
Other OTCTotal Valuation
Guardion Health Sciences, Inc. carries a market capitalization of 4.17M, placing it among publicly traded companies globally. Its enterprise value stands at -8.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.17M |
| Enterprise Value | -8.08M |
Share Statistics
Guardion Health Sciences, Inc. currently has 1.28M shares outstanding.
| Shares Outstanding | 1.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guardion Health Sciences, Inc. trades at a trailing price-to-earnings ratio of 1.06. The price-to-sales ratio is 0.72, and the price-to-book ratio stands at -0.08.
| PE Ratio | 1.06 |
| PS Ratio | 0.72 |
| PB Ratio | -0.08 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | -1.72 |
| P/OCF Ratio | -1.72 |
Enterprise Valuation
| EV / Sales | 0.24 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Guardion Health Sciences, Inc. maintains a current ratio of 16.67, meaning it holds 16.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 16.67 |
| Quick Ratio | 16.17 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 44.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 10.09 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.11 |
Stock Price Statistics
Guardion Health Sciences, Inc.'s stock has gained approximately 0.93167702% over the past 52 weeks. The 50-day moving average sits at 3.22, while the 200-day moving average is 3.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.93167702% |
| 50-Day Moving Average | 3.22 |
| 200-Day Moving Average | 3.55 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guardion Health Sciences, Inc. generated 9.35M in revenue and converted that into 6.37M in net income, yielding earnings per share of -4.75. EBITDA reached -3.83M, while operating income came in at -3.85M.
| Revenue | 9.35M |
| Gross Profit | 4.03M |
| Operating Income | -3.85M |
| Pretax Income | -6.08M |
| Net Income | 6.37M |
| EBITDA | -3.83M |
| EBIT | -3.85M |
| Earnings Per Share (EPS) | -4.75 |
Balance Sheet
Total book value stands at -87.99M, with working capital of 14.37M providing operational flexibility.
| Cash & Cash Equivalents | 14.82M |
| Total Debt | N/A |
| Net Debt | -14.82M |
| Equity (Book Value) | -87.99M |
| Book Value Per Share | -68.78 |
| Working Capital | 14.37M |
Cash Flow
Guardion Health Sciences, Inc. produced -3.92M in operating cash flow over the past twelve months. After subtracting -1.00 in capital expenditures, free cash flow totaled -3.92M - equivalent to -3.06 per share.
| Operating Cash Flow | -3.92M |
| Capital Expenditures | -1.00 |
| Free Cash Flow | -3.92M |
| FCF Per Share | -3.06 |
Margins
Guardion Health Sciences, Inc. operates with a gross margin of 43.07, reflecting its pricing power and cost economics. The operating margin of -41.23 and net profit margin of 68.21 provide insight into operational efficiency.
| Gross Margin | 43.07 |
| Operating Margin | -41.23 |
| Pretax Margin | -65.08 |
| Profit Margin | 68.21 |
| EBITDA Margin | -41.03 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 87.42 |
| FCF Yield | -58.13 |
Stock Splits
Guardion Health Sciences, Inc.'s most recent stock split took place on January 9, 2023 with a 50:1 split ratio.
| Last Split Date | 1/9/2023 |
| Split Ratio | 50:1 |
Scores
Guardion Health Sciences, Inc. posts an Altman Z-Score of -4.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.53 |